Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease...
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...
UCB Convening Notice to the General Meeting of the Shareholders 2024 CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the ordinary...
SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today...
UCB Convocation à L’ Assemblée Générale des Actionnaires 2023 CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’Administration invite les actionnaires à l’assemblée générale...
BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global...
UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022 UCB -Société AnonymeAllée de la Recherche 60, 1070 Bruxellesn° d’entreprise 0403.053.608 (RPM Bruxelles)www.ucb.com(« UCB...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.8 | 2.61723009815 | 183.4 | 193.95 | 181.85 | 203170 | 188.62254885 | DE |
4 | -3.15 | -1.64619806637 | 191.35 | 198.95 | 181.15 | 198640 | 188.69810699 | DE |
12 | 5.15 | 2.81343895111 | 183.05 | 198.95 | 163.4 | 213803 | 183.69942993 | DE |
26 | 29.8 | 18.8131313131 | 158.4 | 198.95 | 141.65 | 205144 | 173.06699565 | DE |
52 | 100.7 | 115.085714286 | 87.5 | 198.95 | 85.76 | 247343 | 142.15517035 | DE |
156 | 99.2 | 111.460674157 | 89 | 198.95 | 65.4 | 269520 | 100.09184225 | DE |
260 | 105.78 | 128.342635283 | 82.42 | 198.95 | 60.18 | 289684 | 95.76552772 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約